Physician profile
Deborah Wu
NPI 1760698245
$3,074.84
in general payments reported to CMS, 2019-2025
20 companies · $868 in 2025
The $868 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $122 · 2020: $59.23 · 2021: $260 · 2022: $683 · 2023: $313 · 2024: $770 · 2025: $868.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,950.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,950.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotissue Holdings INC. | $721.92 | 2021-2025 | |
| Amgen INC. | $513.34 | 2024-2025 | Tepezza |
| Alcon Vision LLC | $509.74 | 2019-2025 | Clareon, Rocklatan, Voyager Dslt |
| Ocular Therapeutix, INC. | $234.26 | 2021-2024 | Dextenza |
| Regeneron Healthcare Solutions, INC. | $151.77 | 2019-2025 | Eylea Hd |
| Johnson & Johnson Surgical Vision, INC. | $146.62 | 2019-2023 | Catalys System |
| Astellas Pharma US INC | $114.30 | 2025 | Izervay |
| Abbvie INC. | $101.42 | 2022-2024 | |
| Dompe US, INC. | $91.88 | 2019-2024 | Oxervate |
| Tarsus Pharmaceuticals, INC. | $87.91 | 2024-2025 | Xdemvy |
| Horizon Therapeutics Plc | $81.37 | 2022-2023 | Tepezza |
| Novartis Pharmaceuticals Corporation | $66.39 | 2020-2022 | |
| Allergan, INC. | $51.01 | 2020-2022 | |
| Apellis Pharmaceuticals, INC. | $48.42 | 2023 | Syfovre |
| Oyster Point Pharma, INC. | $41.86 | 2024 | Ryzumvi, Tyrvaya |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Rayner Intraocular Lenses Limited | $41.42 | 2023-2024 | Rayone Emv, Rayone Spheric, Omidria |
| Aerie Pharmaceuticals, INC. | $21.12 | 2021 | |
| Shire North American Group INC | $19.26 | 2019 | |
| Bausch & Lomb Americas INC. | $19.17 | 2023 | Miebo |
| Genentech USA, INC. | $11.66 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deborah Wu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.